Monsoon brings a welcome break from the scorching heat, but along with the refreshing showers comes a hidden threat—skin infections. As the rains create the perfect breeding ground for bacteria and fungi, our skin becomes more vulnerable to a host of infections. From itchy rashes to more serious conditions like fungal infections and impetigo, the damp and humid weather can wreak havoc on your skin. Here are all the infections you should look out for:

Impetigo is a highly contagious bacterial skin infection that affects the superficial layers of the epidermis (outermost layer of skin). It is most commonly caused by gram-positive bacteria. The infection spreads through direct contact with contaminated surfaces, including rainwater puddles, making it easy to contract during the monsoon.

Ringworm is a highly contagious viral infection, particularly among those with sweaty skin types. It manifests as red, circular spots on areas like the neck, armpits, or foot soles. It spreads through contact with infected surfaces or by scratching affected areas, which can further lead to nail infections.

Athlete’s foot is another common fungal infection, caused by the Candida fungus. It leads to cracked or discoloured patches on the feet and is highly contagious. Walking through rainwater puddles increases the risk of contracting this infection.

Folliculitis is an infection of the hair follicles that results in red bumps on the skin. This condition is caused by both fungal and bacterial infections, often due to excessive sweating and humidity. The combination of rainwater and these factors makes contracting folliculitis more likely during the monsoon.

Eczema is characterized by red, inflamed, and itchy skin with dark, scaly patches. Although non-contagious, this condition can be triggered by external factors such as humidity and genetics. Rainwater can aggravate these symptoms, making it essential to manage exposure during the rainy season.

Mould thrives in damp environments, like wet walls and unused corners of homes during the rainy season. These moulds can trigger allergies such as allergic rhinitis and allergic asthma, as well as increase skin allergies. The presence of mould can exacerbate skin issues, leading to further discomfort.

To protect yourself during the rainy season, avoid walking through puddles, keep your skin dry, and be vigilant about the cleanliness of your surroundings. If you notice any unusual spots or symptoms on your skin, seek medical advice promptly to prevent these infections from worsening.

Long considered a standard tool for assessing body weight, Body Mass Index (BMI) may not be as reliable as once believed. A new study shows that relying on BMI can incorrectly classify people as overweight or obese.

When a team of Italian researchers used the gold standard technique of dual-energy X-ray absorptiometry (DXA) to measure body fat in the general population, they found that the traditional WHO-approved BMI classification system misidentified a significant number of people as having overweight or obesity.

How Is The BMI Wrong?

A total of 1,351 adults of mixed gender aged between 18 and 98 years were checked for their body weight using the DXA system.

The results, published in the journal Nutrients, revealed that more than one-third (34 percent) of those with obesity defined by BMI had been misclassified and should be in the overweight category.

For those with an overweight BMI, DXA showed that more than half – 53 percent – had been misclassified – three quarters of those misclassified fall into the normal weight category, while the other quarter should have been classified as having obesity.

The DXA analysis found that the prevalence of overweight and obesity across the cohort was around 37 percent overall (23.4 percent overweight, and 13.2 percent obesity, compared to 26.2 percent and 14.1 percent with BMI).

“In the past few years, there has been a lot of criticism of the BMI system due to its inability to accurately capture body fat percentage or distribution, to correctly categorise weight status based on adiposity,” said Professor Marwan El Ghoch, of the Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Also read: Your BMI Does Not Reflect Your Health: New Study Warns How It Misses A Key Health Aspect

Despite these concerns, BMI as a weight classification system continues to be used in the general population in primary healthcare (i.e., general practitioners) and non-clinical (i.e., policy and health insurance) settings, he added.

The researchers urged revising public health guidelines to consider combining direct body composition or their surrogate measures, such as skinfold measurement or body circumference, with the waist-to-height ratio, with BMI, while assessing weight status in the general population.

Waist-to-Height Ratio May Be More Accurate: The India Story

In January 2025, India revamped its obesity guidelines, and the new approach focused on abdominal obesity and comorbid diseases, rather than just BMI.

According to the redefining team, it was essential to move beyond BMI-only approaches to tackle the ever-growing number of people related to other major health risks. They stated that while BMI can be a screening tool, obesity must be defined by body fat.

“BMI should be used for screening purposes, but obesity should be confirmed ideally by a measure of body fat wherever feasible, or another measure such as waist circumference, WHR, or Waist-to-height ratio,” Dr. Naval Vikram, Professor of Medicine, at AIIMS, New Delhi, was quoted as saying to IANS at the time.

Also read: 41 million children aged 5-19 living with high BMI in India: Study

What Do The New Guidelines Say

It recognizes abdominal fat — closely linked to insulin resistance — as a key factor in the diagnosis. It integrates the presence of comorbidities — such as diabetes and cardiovascular disease — into the diagnostic process.

The revised guidelines also introduce a two-stage classification system, addressing both generalized and abdominal obesity.

Stage 1 Obesity: Increased adiposity (BMI > 23 kg/m²) without apparent effects on organ functions or routine daily activities.

Stage 2 Obesity: Advanced state of obesity with increased BMI more than 23 kg/2, and abdominal adiposity; excess Waist Circumference or Waist-to-Height Ratio.

Amanda Peet, the Hollywood actress known for roles in Something’s Gotta Give, The Whole Nine Yards, and Jack & Jill, recently opened up about her breast cancer diagnosis and how informing her kids about her health became the toughest part for her.

In a New Yorker essay published March 21, the 54-year-old actress announced how a routine scan in August 2025 showed an unusual ultrasound result. Later, a biopsy detected a tumor that “appeared” small.

The Dirty John star found to be in stage 1 of lobular cancer that is “hormone-receptor-positive” and “HER2-negative,” making her “happier than the pre-diagnosis” stage.

It is because Hormone-receptor-positive and HER2-negative cancer is less aggressive and often easier to treat than more aggressive forms of breast cancer.

However, informing her children, Frances, 19, Molly, 15, and Henry, 11, about the cancer was the toughest part for her, and she had to be in the right mindset before sharing the news with them.

“They've been great,” Peet told E! News.

“I definitely had to get myself together before including them. The hard part was realizing that nothing is certain and there was going to be no perfect time to tell them,” she added.

Peet stated that between her diagnosis, she had also been navigating a series of family health crises — with both of her parents' final months in hospice care.

The Your Friends & Neighbors actress, in her essay, also noted that she would “only need a lumpectomy and radiation,” not a double mastectomy.

Also read: Jane Fallon Diagnosed With Breast Cancer, This Is How She Caught It Early

What is Lobular Cancer?

Invasive Lobular Carcinoma (ILC) the second most common form of breast cancer, representing 5 to 15 percent of breast cancer cases.

Rather than a distinct lump, it can appear as a thickening or "fullness" rather than a tumor.

It is often difficult to detect on mammograms, thus MRI or ultrasound are more effective for detection

It is usually hormone receptor-positive.

Also read: Olivia Munn’s Mom Diagnosed With Breast Cancer After Actor Urges Her To Take Risk Test; What Should You Do If Cancer Runs In Your Family?

What Is Hormone receptor-positive (HR+) and HER2-negative (HER2−) Breast Cancer

HR+ and HER2− breast cancer is the most common subtype and is seen among 60–75 per cent of cases.

It is not two different cancers, but rather specific, defining characteristics of the same cancer type (breast cancer). It grows:

• due to hormones estrogen/progesterone,
• lacks excess HER2 protein,
• it can occur in either or both breasts
• has a better prognosis
• slower growth rate
• often treated with hormone therapy and sometimes chemotherapy.

Why Early Diagnosis Matters for Breast Cancer

According to the Centers for Disease Control and Prevention (CDC), breast cancer screening is a proactive checkup used to find cancer before any physical signs or symptoms appear. While screening doesn’t prevent cancer, its goal is early detection, making the disease much easier to treat.

Since every person’s body and history are different, you and your doctor should engage in informed and shared decision-making. This means discussing the pros and cons to decide together if, and when, screening is right for you.

The US Preventive Services Task Force (a group of national medical experts) provides guidelines based on the latest research:

Average Risk

Women aged 40 to 74 should generally get a mammogram every two years.

High Risk

If you have a family history or other risk factors, your doctor may recommend a different schedule or additional tests.

GLP-1 receptor agonists are a modern class of medicines that have changed the treatment of type 2 diabetes and obesity. In simple terms, they help the body respond to food more smartly. After eating, the intestine naturally sends signals that help regulate sugar and appetite levels.

GLP-1 RA medicines imitate this signal. As a result, blood sugar rises less after meals, appetite becomes more controlled, and many people feel full with smaller amounts of food. This is why these medicines are used not only for diabetes, but also for weight reduction in selected people.

GLP-1 Drugs: Not A Miracle Injection

These medicines are important because their benefits can go beyond sugar control alone. Studies and current diabetes guidelines show that some GLP-1 RAs can reduce body weight, improve long-term sugar levels, and lower the risk of major heart-related problems in people who have type 2 diabetes and high cardiovascular risk.

Recent guidance also supports their use in some people with chronic kidney disease when cardiovascular risk reduction is an important goal. This does not mean every drug in the group is identical, but it means the class has become medically important for more than just lowering sugar.

For the general public, one important point is that these are not “miracle injections.”

They work best when combined with better food choices, regular walking or exercise, good sleep, and medical follow-up. They are usually started slowly because the commonest side effects are stomach-related, such as nausea, vomiting, constipation, loose motions, or a feeling of fullness.

Not everyone is suitable for them, and the decision depends on a person’s diabetes status, weight, heart or kidney disease, other medicines, and cost. Used properly, GLP-1 RAs are powerful tools that can improve health, but they should always be taken under medical supervision.

GLP-1 Drugs: Urgent Need to Curb Misuse

So Indian Medical Association (IMA) is planning to seek a mandate restricting prescriptions of GLP-1 drugs to certified endocrinologists/diabetologists or MD general medicine practitioners to curb indiscriminate use and safeguard patient safety as access expands, many media report in August last year about rampant misuse of GLP1 weight loss drugs by cosmetologists, physiotherapists, dermatologists, general MBBS clinicians, and even ayurveda, and other non-modern medicine practitioners.

Many MBBS, physiotherapists, and non-modern medicine practitioners are prescribing GLP1 drugs to people who neither have diabetes nor any comorbidity or acute obesity, but purely for cosmetic reasons to lose some weight that can be otherwise easily done with some lifestyle changes like exercise and diet.

It is a duty of the government to take care of it because there is a lot of misuse and misprescription that needs to be curbed immediately, because these medicines also have side effects.

We will write to the government to take necessary action to stop the misuse of the drug. We will discuss it in our meeting in the first week of April 2026.